GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Neuphoria Therapeutics Inc (NAS:NEUP) » Definitions » Accumulated other comprehensive income (loss)

NEUP (Neuphoria Therapeutics) Accumulated other comprehensive income (loss) : $-2.43 Mil (As of Sep. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Neuphoria Therapeutics Accumulated other comprehensive income (loss)?

Accumulated other comprehensive income (loss) is the aggregate amount of gains or losses that are not part of retained earnings. Neuphoria Therapeutics's Accumulated other comprehensive income (loss) for the quarter that ended in Sep. 2024 was $-2.43 Mil.

Neuphoria Therapeutics's quarterly Accumulated other comprehensive income (loss) declined from Dec. 2023 ($9.43 Mil) to Jun. 2024 ($-3.01 Mil) but then increased from Jun. 2024 ($-3.01 Mil) to Sep. 2024 ($-2.43 Mil).

Neuphoria Therapeutics's annual Accumulated other comprehensive income (loss) declined from Jun. 2022 ($8.62 Mil) to Jun. 2023 ($-3.06 Mil) but then increased from Jun. 2023 ($-3.06 Mil) to Jun. 2024 ($-3.01 Mil).

Neuphoria Therapeutics Accumulated other comprehensive income (loss) Historical Data

The historical data trend for Neuphoria Therapeutics's Accumulated other comprehensive income (loss) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Neuphoria Therapeutics Accumulated other comprehensive income (loss) Chart

Neuphoria Therapeutics Annual Data
Trend Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24
Accumulated other comprehensive income (loss)
Get a 7-Day Free Trial Premium Member Only Premium Member Only 9.22 8.60 8.62 -3.06 -3.01

Neuphoria Therapeutics Quarterly Data
Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Jun24 Sep24
Accumulated other comprehensive income (loss) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -3.06 - 9.43 -3.01 -2.43

Neuphoria Therapeutics Accumulated other comprehensive income (loss) Calculation

Accumulated other comprehensive income (loss) is the aggregate amount of gains or losses that are not part of retained earnings.

Neuphoria Therapeutics Accumulated other comprehensive income (loss) Related Terms

Thank you for viewing the detailed overview of Neuphoria Therapeutics's Accumulated other comprehensive income (loss) provided by GuruFocus.com. Please click on the following links to see related term pages.

Neuphoria Therapeutics Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Neuphoria Therapeutics Inc (NAS:NEUP) » Definitions » Accumulated other comprehensive income (loss)
Comparable Companies
SMMT INCY MRNA BMRN INSM UTHR SRPT TECH RPRX PCVX VRTX ASX:CSL REGN XKRX:207940 XBRU:UCB XBRU:ARGX ALNY BNTX XKRX:068270 BGNE
Traded in Other Exchanges
B1N0:Germany B1N0:Germany
Address
200 Greenhill Road, Eastwood, SA, AUS, 5063
Website
https://www.bionomics.com.au
Bionomics Ltd is a clinical-stage biopharmaceutical company. It is primarily engaged in the development of therapeutics for diseases of the central nervous system and cancer. The company's reportable segment is the Drug Discovery and Development segment which is engaged in the discovery, development, and commercialization of compounds to match a target product profile. The company generates all of its revenues from Australia.